Literature DB >> 11480447

Estimating risk of breast cancer from population incidence affected by widespread mammographic screening.

R Taylor1, J Boyages.   

Abstract

OBJECTIVES: To estimate the absolute risk of breast cancer in women, allowing for the effect on incidence of the introduction of widespread mammographic screening.
DESIGN: Annual breast cancer incidences were compared with numbers of annual mammograms in the population for 1980-96 to identify periods most likely to be affected by screening. Age specific breast cancer incidences 1972-96 were modelled by Poisson regression with an age, period, and cohort analysis. The 1996 age specific incidence was recalculated with the stable period effect 1972-89, and the age and cohort effects. Age specific incidence was converted to cumulative risk of breast cancer to age 79.
SETTING: Population based data from all women in New South Wales (NSW), Australia. PATIENTS OR PARTICIPANTS: Breast cancer incidence in women 1972-96 obtained from the NSW Central Cancer Registry and female populations derived from successive censuses. Mammographic data from private sector mammograms (1985-96), and the mammographic screening service (1988-96) for NSW women.
INTERVENTIONS: Introduction of population mammographic screening. MAIN OUTCOME MEASURES: Recorded age specific incidence and absolute risk of breast cancer to age 79 was compared with underlying incidence and cumulative absolute risk, adjusted for recent period effects, most likely due to mammographic screening in the population.
RESULTS: The age, period, and cohort model showed an increasing effect for birth cohorts 1910-44 then a plateau, and prominent period effects in 1991 and 1994-6. Increased incidence of breast cancer coincided with an increase in mammographic examinations in the private sector (1991), and prevalent rounds of mammographic screening in the population (1994-6) after introduction of a statewide mammographic screening service. Recorded incidence produced a breast cancer risk to age 79 of 9.9% (1 in 10) for 1996, whereas estimation of underlying incidence yielded a risk of 8.5% (1 in 12).
CONCLUSIONS: The introduction of mammographic screening in a population inflates the incidence of breast cancer because of diagnosis of prevalent cases. For the purpose of public and clinical communication, it is more reasonable and responsible to adjust for period effects (due to screening) rather than produce risk estimates based on recorded incidence, which may show an alarming increase in risk of breast cancer over a short period.

Entities:  

Mesh:

Year:  2001        PMID: 11480447     DOI: 10.1136/jms.8.2.73

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  5 in total

Review 1.  Hormone replacement therapy and breast cancer: estimate of risk.

Authors:  Nathan J Coombs; Richard Taylor; Nicholas Wilcken; John Boyages
Journal:  BMJ       Date:  2005-08-06

2.  Secular trends, race, and geographic disparity of early-stage breast cancer incidence: 25 years of surveillance in Connecticut.

Authors:  J Christopher F Crabbe; David I Gregorio; Holly Samociuk; Helen Swede
Journal:  Am J Public Health       Date:  2015-04-23       Impact factor: 9.308

3.  The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model.

Authors:  Ronald E Gangnon; Brian L Sprague; Natasha K Stout; Oguz Alagoz; Harald Weedon-Fekjær; Theodore R Holford; Amy Trentham-Dietz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-03-18       Impact factor: 4.254

4.  Model of outcomes of screening mammography: information to support informed choices.

Authors:  Alexandra Barratt; Kirsten Howard; Les Irwig; Glenn Salkeld; Nehmat Houssami
Journal:  BMJ       Date:  2005-03-08

5.  A population-based study of breast cancer prevalence in Australia: predicting the future health care needs of women living with breast cancer.

Authors:  Xue Qin Yu; Roberta De Angelis; Qingwei Luo; Clare Kahn; Nehmat Houssami; Dianne L O'Connell
Journal:  BMC Cancer       Date:  2014-12-11       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.